Gold prices just lower; monthly gains on track
Investing.com - Stifel has reiterated its Buy rating and $71.00 price target on Spyre (NASDAQ:SYRE), currently trading at $16.87 with a market cap of $1.02 billion, following the company’s second-quarter 2025 update. According to InvestingPro data, the stock shows significant volatility with a beta of 2.83, making it particularly sensitive to market movements.
The research firm highlighted Spyre’s continued clinical execution, particularly the progress of its SKYLINE-UC platform study, which is advancing after positive Phase 1 readouts from SPY001 (α4β7) and SPY002 (TL1A). InvestingPro analysis indicates the company maintains a FAIR overall financial health score, with strong liquidity ratios supporting its research programs.
Stifel noted that first-in-human data for SPY003 (IL-23p19) is expected in the fourth quarter of 2025, which, if positive, will unlock the third monotherapy cohort and enable expansion of the combination Part B portion of the study.
The firm also pointed out that Spyre’s first-in-human TL1A study has enabled progression of not only SPY002 in inflammatory bowel disease but also SPY072 across a broader set of autoimmune indications, with the company planning to initiate the SKYWAY-RD basket trial in rheumatic diseases in the third quarter of 2025.
According to Stifel, the UC platform trial has begun enrollment with initial data from Part A (open-label monotherapy data for SPY001/002/003) expected in 2026 and Part B combination induction data anticipated in 2027. With analysts maintaining a strong consensus recommendation of 1.17 (where 1 is Strong Buy), the stock appears to be trading below its potential. Get more detailed insights and 8 additional key ProTips with InvestingPro.
In other recent news, Spyre Therapeutics announced positive interim Phase 1 results for its monoclonal antibodies, SPY002 and SPY072, targeting TL1A for immune-mediated diseases. The company reported that both antibodies were well-tolerated with no serious adverse events in single doses up to 1500 mg, and they demonstrated a half-life of approximately 75 days. This development is seen as a significant milestone in the company’s strategy for treating inflammatory bowel disease (IBD). Leerink Partners reiterated its Outperform rating for Spyre, setting a price target of $45.00, citing the potential of the TL1A program as a best-in-class monotherapy. Guggenheim analysts also maintained a Buy rating with a $65 price target, highlighting Spyre’s progress in advancing its pipeline for IBD treatments. Analysts at Guggenheim expressed a positive outlook on Spyre’s potential to develop optimized combination therapies that could outperform current treatments. These developments underscore the company’s ongoing efforts to enhance treatment options for IBD.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.